Harmony Biosciences Holdings (HRMY) Amortization of Deferred Charges (2019 - 2023)

Harmony Biosciences Holdings has disclosed Amortization of Deferred Charges across 5 years of filings, most recently posting $424000.0 for Q2 2023.

• Amortization of Deferred Charges for Q2 2023 came in at $424000.0, up 3.16% year-over-year; the trailing twelve-month figure through Jun 2023 was $1.7 million (down 1.18% YoY), and the FY2022 annual result was $1.7 million, down 25.69% from the prior year.
• Amortization of Deferred Charges came in at $424000.0 for Q2 2023 at Harmony Biosciences Holdings, up from $416000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $1.4 million in Q4 2020 to a low of $185000.0 in Q3 2019.
• The 5-year median for Amortization of Deferred Charges is $417000.0 (2021), against an average of $471750.0.
• Across the five-year window, Amortization of Deferred Charges soared 562.86% in 2020 and tumbled 69.97% in 2021, its largest moves.
• Harmony Biosciences Holdings' Amortization of Deferred Charges stood at $210000.0 in 2019, then jumped by 562.86% to $1.4 million in 2020, then sank by 69.97% to $418000.0 in 2021, then grew by 0.96% to $422000.0 in 2022, then grew by 0.47% to $424000.0 in 2023.
• The last three Amortization of Deferred Charges figures came in at $424000.0 (Q2 2023), $416000.0 (Q1 2023), and $422000.0 (Q4 2022), per Business Quant data.